Pacific Biosciences provides an integrated platform for genetic analysis and its sequencing systems are in use by scientists around the world to drive discovery in human biomedical research, plant and animal sciences, and microbiology. Has had a nice steady run and seems to be able to stay within a tighter 12% trail. RSI is pretty high so if you are looking for an...
im not bullish here, so close to a big monthly resistance. just wait a couple more dollars if you arent in yet...see if it breaks or not! gl
Added today. Looking strong for next few months at least + 220 call options vs 0 put options..
Buying opportunity when price breaks above the top trend line.
Pacific Biosciences of California, Inc. PACB reported fourth-quarter 2019 break-even earnings per share (EPS) versus the Zacks Consensus Estimate of a loss of 16 cents. The company had reported a loss of 21 cents in the year-ago quarter. Revenues of this Zacks Rank #3 (Hold) company totaled $27.93 million, which outpaced the Zacks Consensus Estimate by 9.8%....
Momentum is shifting down. We have multiple gaps to fill and very decent support. If we miss the short we can take longs at the red horizontal lines.
PACB is on a tear right now with new of an acquisition deal by their competitor Illumina for 1.2 billion dollars. According to Forbes, this is the largest deal Illumina has ever made in more than 20 years. According to other reports the deal won't be finalized till mid-2019 though, so today's price increase seems to a result of that new breaking yesterday after...
PACB Swing Setup 6-16-17. Waiting for 20, 50 & 100 MA's to come back toward the 200 MA and for price to breach the 200. No position currently.
genome sequencing technology.presenting at rbc conf 22-25 nyc.